Glucagon
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 1
Conditions
Diabetes Mellitus, Type 1
Trial Timeline
Mar 27, 2017 → Sep 27, 2017
NCT ID
NCT03091673About Glucagon
Glucagon is a phase 3 stage product being developed by Xeris Pharmaceuticals for Diabetes Mellitus, Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT03091673. Target conditions include Diabetes Mellitus, Type 1.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 1 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03255629 | Phase 1/2 | Completed |
| NCT03091673 | Phase 3 | Completed |
| NCT02937558 | Phase 2 | Completed |
| NCT02423980 | Phase 2 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 1